SCHEMBL2818945

SCHEMBL2818945

OCc1cnn(Cc2ccc(-c3ccccc3)cc2)c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.63
EPHB4 P54760 2/20 0.46
KDR P35968 2/20 0.46
CREBBP Q92793 3/20 0.46
TEK Q02763 2/20 0.46
HSP90AB1 P08238 2/20 0.46
HDAC1 Q13547 1/20 0.45
KCNH2 Q12809 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
NAMPT P43490 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
FYN P06241 1/20 0.41
SCD O00767 1/20 0.41
SCD5 Q86SK9 1/20 0.41
KLKB1 P03952 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1244019 0.90 L3MBTL1 (0.61) L3MBTL1CREBBPHDAC1HSD17B10ADORA2A
SCHEMBL25365603 0.86 L3MBTL1 (0.76) L3MBTL1EPHB4KDRCREBBPKCNH2
SCHEMBL3103391 0.81 NOTUM (0.54) L3MBTL1KCNH2HSD17B10
SCHEMBL2821950 0.80 HSD17B10 (0.43) L3MBTL1EPHB4KDRTEKKCNH2
SCHEMBL3085851 0.80 LMNA (0.61) L3MBTL1CREBBPKCNH2HSD17B10SCD5
SCHEMBL2819206 0.78 HSP90AB1 (0.49) L3MBTL1HSP90AB1HDAC1KLKB1
SCHEMBL3085028 0.76 GAA (0.55) L3MBTL1HSD17B10
SCHEMBL18235821 0.76 KMT2A (0.66) L3MBTL1KCNH2HSD17B10
SCHEMBL2822506 0.76 HSD17B10 (0.40) L3MBTL1KCNH2HSD17B10KLKB1
SCHEMBL2052581 0.76 L3MBTL1 (0.52) L3MBTL1HSP90AB1ADORA2AADORA1KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184815-A1 AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184815-A1 AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA PPARA, PPARD, PPARG L3MBTL1 4855/4885EPHB4 1067/4885KDR 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.